Mont-Saint-Guibert, Belgium
Launched in April 2022, Cellistic specializes in process development and manufacture of cell therapies based on human induced pluripotent stem cell (iPSC) technology. The company’s focus and expertise in iPSC generation and differentiation protocol development makes it well-positioned to partner with innovative cell therapy developers to establish novel advanced therapies. With more than a decade of scientific and technical knowledge transfer from sister company Ncardia, Cellistic is uniquely experienced in designing and optimizing manufacturing procedures for iPSCs that deliver quality products at scale.
No key contacts have been added to this profile yet.
No reviews have been added to this profile yet.
This is the company profile page for Cellistic on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.
